Albireo Pharma Inc
ALBO
ALBO was delisted on the 2nd of March, 2023.
3 hedge funds and large institutions have $2.04M invested in Albireo Pharma Inc in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 92 closing their positions.
97% less funds holding
Funds holding: 96 → 3 (-93)
99% less capital invested
Capital invested by funds: $396M → $2.04M (-$394M)
100% less funds holding in top 10
Funds holding in top 10: 4 → 0 (-4)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 92
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$42.3M |
| 2 |
PA
Perceptive Advisors
New York
|
-$38M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$36.8M |
| 4 |
CC
Chicago Capital
Chicago,
Illinois
|
-$29.4M |
| 5 |
BlackRock
New York
|
-$29.1M |
ALBO Hedge Fund Activity: Q1 2023 in Review
3 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Albireo Pharma Inc (ALBO) for Q1 2023, worth a combined $2.04M — down 99% from $396M a quarter earlier.
Sellers outnumbered buyers: 92 funds closed out of ALBO and 0 opened new positions — a net loss of 92 holders — while 2 trimmed existing stakes and 0 added.
The largest seller was Federated Hermes, exiting entirely with an estimated $42.3M sold.
- 3 institutional investors held Albireo Pharma Inc (ALBO) as of Q1 2023, down from 96 in Q4 2022.
- Funds reported $2.04M of Albireo Pharma Inc stock for Q1 2023, down 99% quarter-over-quarter.
- 0 funds opened new Albireo Pharma Inc positions in Q1 2023 and 92 closed out, a net change of -92 holders.
- The largest Albireo Pharma Inc seller in Q1 2023 was Federated Hermes, an estimated $42.3M sold.
Based on aggregated 13F filings for Q1 2023.